Olga Ochoa-Gondar

Summary

Country: Spain

Publications

  1. ncbi Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study
    Olga Ochoa-Gondar
    Research Unit, Primary Care Service of Tarragona Valls, Institut Catala de la Salut, Tarragona, Spain
    Vaccine 26:1955-62. 2008
  2. ncbi The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study
    Olga Ochoa-Gondar
    Primary Care Service of Tarragona Valls, Institut Catala de la Salut, Tarragona, Spain
    BMC Public Health 8:222. 2008
  3. ncbi Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up
    Angel Vila-Corcoles
    Primary Care Service of Tarragona, EPIVAC Study Group, Institut Catala de la Salut, Tarragona, Spain
    BMC Public Health 12:222. 2012
  4. ncbi Epidemiology of community-acquired pneumonia in older adults: a population-based study
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, Institut Catala de la Salut, Prat de la Riba 39, Tarragona 43001, Spain
    Respir Med 103:309-16. 2009
  5. ncbi Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia
    Angel Vila-Corcoles
    Research Unit, Primary Health Care Service of Tarragona Valls, Institut Català de Salut, Tarragona, Spain
    BMC Infect Dis 9:36. 2009
  6. ncbi Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, Catalonian Health Institute, Tarragona, 43001, Spain
    Clin Infect Dis 43:860-8. 2006
  7. ncbi Invasive pneumococcal disease in Catalonian elderly people, 2002-2009: serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, Institut Català de Salut, Tarragona, Spain
    Vaccine 29:7430-4. 2011
  8. ncbi Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, EVAN Study Group, Catalonian Health Institute, District of Tarragona, Catalonia, Spain
    BMC Public Health 6:231. 2006
  9. ncbi Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, Institut Catala de la Salut, Tarragona, Spain
    BMC Infect Dis 10:73. 2010
  10. ncbi Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, Institut Catala de la Salut, Tarragona, Spain
    Hum Vaccin Immunother 8:639-44. 2012

Detail Information

Publications15

  1. ncbi Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study
    Olga Ochoa-Gondar
    Research Unit, Primary Care Service of Tarragona Valls, Institut Catala de la Salut, Tarragona, Spain
    Vaccine 26:1955-62. 2008
    ..66; 95% CI: 0.43-1.01; p=0.059). Although our findings suggest moderate benefits from the vaccination, the evidence of clinical effectiveness appears limited...
  2. ncbi The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study
    Olga Ochoa-Gondar
    Primary Care Service of Tarragona Valls, Institut Catala de la Salut, Tarragona, Spain
    BMC Public Health 8:222. 2008
    ..However, population-based data are very limited and its overall burden is unclear. This study assessed incidence and mortality from CAP among Spanish community-dwelling elderly...
  3. ncbi Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up
    Angel Vila-Corcoles
    Primary Care Service of Tarragona, EPIVAC Study Group, Institut Catala de la Salut, Tarragona, Spain
    BMC Public Health 12:222. 2012
    ..This study assessed the clinical effectiveness of the 23-valent polysaccharide pneumococcal vaccine (PPV23) against acute myocardial infarction and ischaemic stroke in older adults...
  4. ncbi Epidemiology of community-acquired pneumonia in older adults: a population-based study
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, Institut Catala de la Salut, Prat de la Riba 39, Tarragona 43001, Spain
    Respir Med 103:309-16. 2009
    ..This study assessed incidence, aetiology, clinical outcomes and risk factors for community-acquired pneumonia (CAP) in older adults...
  5. ncbi Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia
    Angel Vila-Corcoles
    Research Unit, Primary Health Care Service of Tarragona Valls, Institut Català de Salut, Tarragona, Spain
    BMC Infect Dis 9:36. 2009
    ..This study assessed current levels of penicillin resistance among Streptococcus Pneumoniae causing pneumonia in Spanish middle age and older adults...
  6. ncbi Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, Catalonian Health Institute, Tarragona, 43001, Spain
    Clin Infect Dis 43:860-8. 2006
    ..However, the effectiveness of the 23-valent PPV remains controversial. We assessed the effectiveness of this vaccine in older adults...
  7. ncbi Invasive pneumococcal disease in Catalonian elderly people, 2002-2009: serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, Institut Català de Salut, Tarragona, Spain
    Vaccine 29:7430-4. 2011
    ..As main conclusion, in our setting, the PCV-13 has almost similar serotype coverage to the PPV-23 in preventing IPD among the elderly population, which suggests a possible future use of the conjugate vaccine in all age groups...
  8. ncbi Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, EVAN Study Group, Catalonian Health Institute, District of Tarragona, Catalonia, Spain
    BMC Public Health 6:231. 2006
    ..We analysed the evolution of the pneumococcal vaccination rates from 2000 to 2003...
  9. ncbi Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, Institut Catala de la Salut, Tarragona, Spain
    BMC Infect Dis 10:73. 2010
    ..However, its efficacy in preventing pneumococcal infections remains controversial. This study assessed the clinical effectiveness of vaccination against invasive pneumococcal disease (IPD) among people over 60 years...
  10. ncbi Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, Institut Catala de la Salut, Tarragona, Spain
    Hum Vaccin Immunother 8:639-44. 2012
    ..This study assessed the clinical effectiveness of vaccination against pneumonia among patients with chronic pulmonary diseases...
  11. ncbi Incidence of invasive pneumococcal disease among elderly people in Southern Catalonia, Spain, 2002-2009: an increase in serotypes not contained in the heptavalent conjugate vaccine
    Olga Ochoa-Gondar
    Primary Care Service of Tarragona Valls, EPIVAC Study Group, Institut Catala de la Salut, Av Prat de la Riba 39, 43001 Tarragona, Spain
    J Infect 63:434-40. 2011
    ..According to these findings, Southern Catalonia region can be classified as a mesoendemic area of pneumococcal infections among elderly people, with a recent increase incidence of some nonPCV7 serotypes (especially 19A)...
  12. ncbi Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, Institut Catala de la Salut, Tarragona, Spain
    BMC Public Health 10:25. 2010
    ..The main objective of this study is to evaluate the clinical effectiveness of PPV-23 in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the general population over 60 years...
  13. ncbi Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview
    Angel Vila-Corcoles
    Primary Care Service of Tarragona, EPIVAC Study Group, Institut Catala de la Salut, Prat de la Riba 39, 43001, Tarragona, Spain
    Expert Rev Vaccines 11:221-36. 2012
    ..This paper reviews available data on the efficacy and effectiveness of polysaccharide pneumococcal vaccination among adults with chronic respiratory diseases...
  14. ncbi [Influenza vaccination and mortality in the elderly]
    Angel Vila-Corcoles
    Servicio de Atención Primaria de Tarragona Valls, Institut Catala de la Salut, Tarragona, Spain
    Med Clin (Barc) 125:689-91. 2005
    ..We evaluated the effectiveness of IV in the reduction of mortality in individuals over 65 years of age...
  15. ncbi Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study
    Angel Vila-Corcoles
    Primary Care Service of Tarragona Valls, EPIVAC Study Group, Institut Catala de la Salut, Prat de la Riba 39, Tarragona 43001, Spain
    Vaccine 27:1504-10. 2009
    ..24; 95% CI: 0.09-0.66). These findings confirm the effectiveness of the vaccine against invasive disease, but they also support the benefit of vaccination in preventing nonbacteremic pneumococcal pneumonia...